Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 5Cyclophosphamide 4Carboplatin 4Filgrastim 3fludarabine 2Thiotepa 2Temozolomide 2Riluzole 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Immunohistochemistry 2Drug Therapy 2Counseling 2Bupropion 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tasquinimod 1sodium thiosulfate 1sargramostim 1saracatinib 1poly ICLC 1pertuzumab 1liposomal doxorubicin 1lenvatinib 1ixabepilone 1etoposide phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × tasquinimod × Gynecologic × Clear all
NCT01743469 2019-01-08

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Ipsen

Phase 2 Completed
201 enrolled 23 charts
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Liver Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡